HC Wainwright Reiterates Buy Rating on Achieve Life Sciences, Inc. (ACHV)
HC Wainwright maintains its buy rating for Achieve Life Sciences with a $12 price target, a 119.38% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating for Achieve Life Sciences (ACHV) with a $12 target on June 22, 2026.
- HC Wainwright's $12 price target implies 119.38% upside from Achieve Life Sciences, Inc.'s ($ACHV) current $5.47 share price.
- Achieve Life Sciences, Inc. traded at $5.29 on Tuesday, with a market cap of about $523.6 million and a 52-week high of $6.16.
- Vanguard Capital Management LLC opened a new position in Achieve Life Sciences with 2,204,714 shares valued at approximately $6.48 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reiterated its buy rating for Achieve Life Sciences, Inc. (NASDAQCM:ACHV), setting a price target of $12. This update came on June 22, 2026, as the firm continues to show confidence in Achieve's potential. On Tuesday, shares of Achieve Life Sciences traded at $5.29.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Achieve Life Sciences
Vanguard Capital Management LLC opened a new position in Achieve Life Sciences, acquiring 2,204,714 shares valued at about $6.48 million. Meanwhile, Millennium Management LLC reduced its holdings by 281,778 shares, leaving it with 1,077,338 shares worth around $3.17 million. Other major holders, including Franklin Resources Inc. and Propel Bio Management, LLC, maintained their positions.
Achieve Life Sciences, Inc. Stock Down 32.5%
Shares of Achieve Life Sciences traded near $5.29 on Tuesday. The company has a market cap of approximately $523.6 million and a forward P/E that is not meaningful due to its lack of profitability. Achieve's beta is 2.264, indicating higher volatility compared to the market. The stock has seen a 52-week low of $2.00 and a high of $6.16, with a 50-day moving average of $4.79 and a 200-day moving average of $4.33.
$ACHV price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Achieve Life Sciences, Inc.
Several insiders have been active in purchasing shares of Achieve Life Sciences recently. On May 29, 2026, Reid Alexander Waldman and Jeffrey Farrow each bought 47,250 shares. Earlier, on May 11, Christopher Nathan Martin acquired the same number of shares. Additionally, on April 18, CEO Andrew Goldberg made multiple purchases, including 11,706,270 shares.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. reiterated its buy rating for Achieve Life Sciences with a $12 price target. Previously, Canaccord Genuity initiated coverage with a buy rating and a $13 target on April 21, 2026. The consensus among analysts, with nine opinions, suggests a mean target price of $13.11.
About Achieve Life Sciences
Achieve Life Sciences, Inc. is a biotechnology company based in Bothell, Washington. It focuses on developing and commercializing cytisinicline, a treatment for nicotine addiction. The company operates in Canada, the United States, and the United Kingdom and has partnerships with Sopharma AD and the University of Bristol. Led by CEO Dr. Andrew D. Goldberg, Achieve has 28 employees.
Bottom Line
HC Wainwright's continued buy rating for Achieve Life Sciences with a $12 target reflects optimism about the company's future. Investors keep an eye on these ratings as they can influence market perceptions. It's important to remember that such analyst ratings are based on past performance and expectations, not real-time data.
Get Achieve Life Sciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ACHV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.